Clearside Biomedical CLSD Stock
Clearside Biomedical Price Chart
Clearside Biomedical CLSD Financial and Trading Overview
| Clearside Biomedical stock price | 0.89 USD |
| Previous Close | 1.33 USD |
| Open | 1.38 USD |
| Bid | 0 USD x 2900 |
| Ask | 0 USD x 1000 |
| Day's Range | 1.32 - 1.47 USD |
| 52 Week Range | 0.9 - 1.86 USD |
| Volume | 317.12K USD |
| Avg. Volume | 165.83K USD |
| Market Cap | 86.33M USD |
| Beta (5Y Monthly) | 2.093309 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.45 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.67 USD |
CLSD Valuation Measures
| Enterprise Value | 41.82M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.3728814 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 87.73632 |
| Price/Book (mrq) | 31.818182 |
| Enterprise Value/Revenue | 42.5 |
| Enterprise Value/EBITDA | -1.388 |
Trading Information
Clearside Biomedical Stock Price History
| Beta (5Y Monthly) | 2.093309 |
| 52-Week Change | -4.10% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.86 USD |
| 52 Week Low | 0.9 USD |
| 50-Day Moving Average | 1.12 USD |
| 200-Day Moving Average | 1.22 USD |
CLSD Share Statistics
| Avg. Volume (3 month) | 165.83K USD |
| Avg. Daily Volume (10-Days) | 131.49K USD |
| Shares Outstanding | 61.67M |
| Float | 53.69M |
| Short Ratio | 5.74 |
| % Held by Insiders | 7.45% |
| % Held by Institutions | 28.12% |
| Shares Short | 626.11K |
| Short % of Float | 1.09% |
| Short % of Shares Outstanding | 1.01% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -3072.76% |
| Gross Margin | 79.26% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -46.80% |
| Return on Equity (ttm) | -201.046% |
Income Statement
| Revenue (ttm) | 984K USD |
| Revenue Per Share (ttm) | 0.02 USD |
| Quarterly Revenue Growth (yoy) | -98.79% |
| Gross Profit (ttm) | 1.12M USD |
| EBITDA | -30122000 USD |
| Net Income Avi to Common (ttm) | -34583000 USD |
| Diluted EPS (ttm) | -0.6 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 41.42M USD |
| Total Cash Per Share (mrq) | 0.67 USD |
| Total Debt (mrq) | 1.22M USD |
| Total Debt/Equity (mrq) | 45.3 USD |
| Current Ratio (mrq) | 8.541 |
| Book Value Per Share (mrq) | 0.044 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -24452000 USD |
| Levered Free Cash Flow (ttm) | -17350750 USD |
Profile of Clearside Biomedical
| Country | United States |
| State | GA |
| City | Alpharetta |
| Address | 900 North Point Parkway |
| ZIP | 30005 |
| Phone | (678) 270-3631 |
| Website | https://clearsidebio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 36 |
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Q&A For Clearside Biomedical Stock
What is a current CLSD stock price?
Clearside Biomedical CLSD stock price today per share is 0.89 USD.
How to purchase Clearside Biomedical stock?
You can buy CLSD shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Clearside Biomedical?
The stock symbol or ticker of Clearside Biomedical is CLSD.
Which industry does the Clearside Biomedical company belong to?
The Clearside Biomedical industry is Biotechnology.
How many shares does Clearside Biomedical have in circulation?
The max supply of Clearside Biomedical shares is 75.84M.
What is Clearside Biomedical Price to Earnings Ratio (PE Ratio)?
Clearside Biomedical PE Ratio is now.
What was Clearside Biomedical earnings per share over the trailing 12 months (TTM)?
Clearside Biomedical EPS is -0.45 USD over the trailing 12 months.
Which sector does the Clearside Biomedical company belong to?
The Clearside Biomedical sector is Healthcare.
Clearside Biomedical CLSD included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17348.82 USD — |
-4.66
|
5.43B USD — | 17339.76 USD — | 17868.07 USD — | — - | 5.43B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 1896.52 USD — |
-3.09
|
— — | 1875.89 USD — | 1933.24 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4496.78 USD — |
-0.21
|
— — | 4456.6 USD — | 4533.11 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 978.2 USD — |
-1.48
|
— — | 969.7 USD — | 989.76 USD — | — - | — — |
- {{ link.label }} {{link}}